THE FOUNDER’S WEEKLY CATCH
Remarkable medical claims are easy to catch. Reliable evidence takes a little more work.
Every week, Dr. Wright’s Stringer pulls interesting medical, longevity, peptide, biotechnology, and regenerative-medicine stories from the fast-moving current of public attention.
DR. WRIGHT’S STRINGER
Catching Tomorrow’s Medicine Today
AI Can Design a Drug in Days. So Why Does It Still Take Years to Reach a Patient?
Imagine asking a computer to help identify a biological target, generate new molecular structures, predict which candidates might bind, estimate useful properties, reject weak candidates, and hand scientists a shortlist.
That sounds like science fiction. It is increasingly becoming pharmaceutical research.
But there is an important catch: AI can accelerate the search for a drug. It cannot yet accelerate biology at the same speed.
What AI is actually changing
AI is already being used in target identification, protein-structure prediction, virtual screening, de novo molecule generation, lead optimization, ADME and toxicity prediction, literature analysis, and parts of clinical-trial planning.
The clearest gains so far are at the front end of discovery: searching enormous chemical spaces and prioritizing candidates before scientists spend time and money synthesizing and testing them.
The reality check
A molecule that looks excellent computationally can fail in a cell. A compound that works in animals can fail in humans. A drug can hit its intended target and still prove too toxic—or simply fail to improve the disease.
That is why “designed in days” does not mean “medicine in days.” Chemistry, preclinical validation, toxicology, manufacturing, Phase I, Phase II, Phase III, and regulatory review remain formidable gates.
One of the field’s biggest tests: rentosertib
Insilico Medicine’s rentosertib, being developed for idiopathic pulmonary fibrosis, is an important real-world test. AI was used in identifying the TNIK target and designing the molecule. After early clinical development and Phase II testing, Insilico announced advancement into Phase III in 2026.
That milestone matters because it moves the AI-drug story beyond attractive computer models and into the place where every medicine ultimately has to prove itself: real patients.
The bottleneck may be shifting
The old question was often: Which molecule should we try?
AI is getting dramatically better at narrowing that search.
The next question is harder: Was the prediction biologically correct?
And biology still gets the final vote.
What comes next: AI research partners
The next evolution goes beyond one algorithm generating one molecule. Researchers are connecting AI systems with scientific literature, molecular-design programs, laboratory automation, biological assays, experimental databases, and clinical-development planning.
The long-term vision is sometimes described as “prompt-to-drug”: AI helps coordinate target discovery, chemistry, synthesis, testing, interpretation, and iteration.
That does not mean scientists disappear. It could mean scientists gain a far more powerful starting point—and the ability to explore parts of chemical and biological space that humans could never search manually.
THE STRINGER
CLAIM: “AI can design a drug in days.”
WHAT THE EVIDENCE SAYS: Some portions of early molecular design and candidate generation can indeed be compressed dramatically.
CLAIM: “Making one still takes months.”
WHAT THE EVIDENCE SAYS: Often much longer. Synthesis, validation, preclinical work, clinical trials, manufacturing, and regulatory review can still require years.
WHAT HAS CHANGED: AI is rapidly shrinking parts of the discovery search.
WHAT HASN’T: Patient safety and clinical proof remain the gatekeepers.
What Founders Is Watching
The first AI-discovered drug to receive full regulatory approval; whether AI-generated candidates fail less often in clinical trials; AI-connected robotic laboratories; and whether these systems uncover treatments humans would never have thought to build.
The real revolution may not simply be faster drug development. It may be access to medicines hidden in chemical spaces we have never been able to explore.
— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education
Sources: Nature Reviews Drug Discovery (2026): AI drug discovery perspective | Insilico Medicine: rentosertib Phase III | Insilico Medicine: rentosertib program | Drug Discovery Today (2026): AI agents in drug discovery
Dr. Wright’s Stringer explores emerging medical research and technology. This article is educational and is not medical advice. Investigational drugs discussed here are not presented as established treatments.
DR. WRIGHT’S STRINGER
Catching Tomorrow’s Medicine Today
Living With Lupus?
Could Exosomes Open a New Door?
Tired of the fatigue, muscle pain, weakness, and unpredictable flares?
Tired of explaining why you look well—even when you feel anything but well?
Ever wonder how much longer it will be before better treatments—or perhaps even a cure—are finally within reach?
Living with lupus can mean waking up each morning without knowing what kind of day your body will allow you to have.
A good day may be followed by crushing exhaustion. Aching muscles and joints can make ordinary activities feel overwhelming. Concentration may disappear. Symptoms can improve, return, or change without warning.
And because so much of lupus can be invisible, friends, coworkers, and even family members may not fully understand what you are carrying.
But researchers are continuing to look for better answers—and one emerging area of study is especially fascinating.
What Are Exosomes?
Every cell in the body needs a way to communicate.
One way cells exchange information is through extremely small packages called extracellular vesicles. Exosomes are one type of these microscopic messengers.
They can carry proteins, genetic instructions, and other biological signals from one cell to another. Those messages may influence inflammation, immune activity, healing, and how surrounding cells behave.
Researchers are now asking an important question:
Could these cellular messages eventually help us redirect an immune system that has mistakenly begun attacking the body?
Why Could This Matter in Lupus?
Lupus is an autoimmune disease. Instead of protecting the body only from outside threats, the immune system can become misdirected and attack the body’s own tissues.
That can affect the joints, muscles, skin, blood vessels, kidneys, heart, lungs, nervous system, and other organs.
Exosomes appear to participate in this complicated immune conversation. Some may carry signals that contribute to inflammation. Others—particularly extracellular vesicles produced by certain stem cells—are being studied for their potential to encourage a calmer, more balanced immune response.
In laboratory and animal research, scientists have reported effects involving:
- The regulation of inflammatory signals
- Communication between immune cells
- T-cell and B-cell activity
- Macrophages that help clear damaged or dying cells
- Biological pathways involved in lupus-related kidney injury
- The restoration of healthier immune balance
That does not mean that an approved exosome treatment for lupus has arrived.
It means researchers may have discovered another way to listen to—and perhaps someday influence—the messages passing between immune cells.
A New Way of Thinking
Most lupus treatments work by suppressing or modifying parts of the immune response.
Exosome research raises a different possibility.
What if future treatments could deliver carefully selected biological messages that help immune cells behave differently?
What if scientists could quiet damaging inflammation without simply shutting down broad portions of the immune system?
What if the body’s own communication system could eventually become part of the treatment?
Those questions have not yet been answered—but they are now being seriously investigated.
And that is where hope begins.
What About Peptides?
Peptides are another way cells and tissues communicate. These small chains of amino acids can participate in inflammation, immune signaling, tissue repair, metabolism, and many other biological processes.
The Founders Peptide Library contains physician-developed educational monographs examining peptides connected with these pathways.
Readers interested in lupus may wish to explore our materials on peptides being investigated in relation to inflammation and immune regulation, including KPV, as well as other research compounds associated with tissue response and recovery.
These peptides are not presented as proven treatments or cures for lupus. The library is designed to help readers understand the emerging biology, the research, the unanswered questions, and the possibilities scientists are exploring.
THE STRINGER
Exosomes are not an established lupus treatment—but this story is about more than whether a treatment is available today.
It is about where medicine may be going next.
For people who have spent years living between flares, appointments, medication changes, and unanswered questions, progress can feel painfully slow. Yet research is moving forward in ways that were difficult to imagine only a generation ago.
Scientists are learning more about how immune cells communicate, why those messages sometimes go wrong, and whether healthier instructions might someday be delivered back into the system.
Every treatment we rely on today began with someone asking a question that medicine could not yet answer.
Could exosomes help open a new door for people living with lupus?
We do not know yet.
But the door is being studied—and Founders will continue watching it.
Want Us to Keep You Updated?
You should not have to search through medical journals and internet headlines to learn when something important changes.
Use the “Stay Informed” email signup below. We will regularly share meaningful developments involving new lupus treatments and medications, emerging exosome research, clinical trials and enrollment opportunities, and immune-regulation discoveries—explained in language you can actually understand.
Stay informed. Keep asking questions. And do not let go of hope.
The next meaningful lupus breakthrough may already be taking shape.
Let’s follow it together.
— Milton Wright, DO, FACOFP
Founding Director
Founders Institute of Medicine & Education
Sources: MSC-derived exosome research in systemic lupus erythematosus | Extracellular vesicles and immune responses in experimental lupus nephritis | Review of exosome research in systemic lupus erythematosus | Review of exosomes and microRNAs in lupus research
Dr. Wright’s Stringer explores emerging medical research and technology. This article is educational and is not medical advice. Exosome-based therapy is not an established or approved treatment for lupus; patients should discuss treatment decisions with qualified healthcare professionals.
Caught Something Interesting?
Send us the product, headline, advertisement, video, or medical claim you would like Founders to investigate.
Curiosity is welcome. Evidence decides what stays on the stringer.
Educational information only. Not medical advice. Research summaries may change as new evidence becomes available.